Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Proteinuric Kidney Disease: early-phase trial registry
3 of 3 indexed Proteinuric Kidney Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Proteinuric Kidney Disease: 3 US clinical trials tracked, 3 recruiting.
Proteinuric Kidney Disease is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 2 of these trials.
Enrollment posture brief
Registry condition proteinuric-kidney-disease
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Proteinuric Kidney Disease lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Proteinuric Kidney Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Proteinuric Kidney Disease is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
NCT05312879
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Maze Therapeutics
NCT06830629
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Vertex Pharmaceuticals Incorporated
NCT06794996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Proteinuric Kidney Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Proteinuric Kidney Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Proteinuric Kidney Disease page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Proteinuric Kidney Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vertex Pharmaceuticals Incorporated sponsors the most Proteinuric Kidney Disease trials on record, review their full trial history before evaluating a specific study. See Vertex Pharmaceuticals Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Proteinuric Kidney Disease condition card totals 3 registered trials; most-linked intervention MZE829; top US site state Alabama. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.